Potential role of "omics" technique in prenatal diagnosis of congenital heart defects.

Congenital heart defect (CHD) is one of the most common birth defects and is the leading cause of neonatal death. Currently, there are no biomarkers available for prenatal diagnosis of CHD. Clinical strategies to diagnose CHD mostly depend on fetal echocardiography. Recent advances in "omics" techniques have opened up new possibilities for biomarker discoveries. In this review, we discuss recent advances in prenatal detection of CHD using biomarkers obtained by "omics" approaches, including genomics, proteomics, metabolomics, and others. There is great potential in obtaining various kinds of parameters using "omics" studies to facilitate early and accurate diagnosis of CHD.

• Publication year

  2018

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2018-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cca.2018.04.011PMID 29649453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges in non‐invasive prenatal screening for sub‐chromosomal copy number variations using cell‐free DNA

  2017cited by this paper
• Prenatal diagnosis of congenital heart diseases by fetal echocardiography in second trimester: a Chinese multicenter study

  2017cited by this paper
• MicroRNA-1 upregulation promotes myocardiocyte proliferation and suppresses apoptosis during heart development.

  2017cited by this paper
• miR-873 suppresses H9C2 cardiomyocyte proliferation by targeting GLI1.

  2017cited by this paper
• Correlation between fetal autopsy and prenatal diagnosis by ultrasound: A systematic review.

  2017cited by this paper
• Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population.

  2016cited by this paper
• Clinical experience with single‐nucleotide polymorphism‐based non‐invasive prenatal screening for 22q11.2 deletion syndrome

  2016cited by this paper
• Identification of Biomarkers by Proteomics for Prenatal Screening for Neural Tube Defects.

  2016cited by this paper
• Maternal plasma mRNA species in fetal heart defects: a potential for molecular screening

  2016cited by this paper
• Using fetal cells for prenatal diagnosis: History and recent progress

  2016cited by this paper
• What Is New in Genetics of Congenital Heart Defects?

  2016cited by this paper
• Stable isotope dimethyl labelling for quantitative proteomics and beyond

  2016cited by this paper
• Neonatal management and outcomes of prenatally diagnosed CHDs

  2016cited by this paper
• Serum markers of pre‐eclampsia identified on proteomics

  2016cited by this paper
• Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects

  2016cited by this paper
• Prenatal detection of congenital heart disease—results of a national screening programme

  2016cited by this paper
• MiRNA-145 Regulates the Development of Congenital Heart Disease Through Targeting FXN

  2016cited by this paper
• A systematic review of prenatal screening for congenital heart disease by fetal electrocardiography

  2016cited by this paper
• Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics

  2015cited by this paper
• DNA methylation abnormalities in congenital heart disease

  2015cited by this paper
• The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research.

  2015cited by this paper
• Epitranscriptional regulation of cardiovascular development and disease

  2015cited by this paper
• Screening and identification of potential predictive biomarkers for Down’s syndrome from second trimester maternal serum

  2015cited by this paper
• Array comparative genomic hybridization and fetal congenital heart defects: a systematic review and meta‐analysis

  2015cited by this paper
• Prenatal Diagnosis of DNA Copy Number Variations by Genomic Single-Nucleotide Polymorphism Array in Fetuses with Congenital Heart Defects

  2015cited by this paper
• Elevated hsa-miR-99a levels in maternal plasma may indicate congenital heart defects.

  2015cited by this paper
• Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications.

  2015cited by this paper
• The Role of RNAs and microRNAs in Non-Invasive Prenatal Diagnosis

  2014cited by this paper
• Prenatal diagnosis of congenital heart defect by genome‐wide high‐resolution SNP array

  2014cited by this paper
• Comparing SILAC- and Stable Isotope Dimethyl-Labeling Approaches for Quantitative Proteomics

  2014cited by this paper
• Maternal plasma RNA sequencing for genome-wide transcriptomic profiling and identification of pregnancy-associated transcripts.

  2014cited by this paper
• Maternal Cell free DNA based screening for fetal microdeletion and the importance of careful diagnostic follow up

  2014cited by this paper
• Quantitative Proteomic Analysis of Serum from Pregnant Women Carrying a Fetus with Conotruncal Heart Defect Using Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Labeling

  2014cited by this paper
• Metabolomic prediction of fetal congenital heart defect in the first trimester.

  2014cited by this paper
• Association of promoter methylation statuses of congenital heart defect candidate genes with Tetralogy of Fallot

  2014cited by this paper
• Noninvasive in vivo monitoring of tissue-specific global gene expression in humans

  2014cited by this paper
• Probabilistic method for detecting copy number variation in a fetal genome using maternal plasma sequencing

  2014cited by this paper
• The Epigenome View: An Effort towards Non-Invasive Prenatal Diagnosis

  2014cited by this paper
• Proteomic study reveals plasma protein changes in congenital heart diseases.

  2014cited by this paper
• Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects.

  2013cited by this paper
• Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis

  2013cited by this paper
• Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA.

  2013cited by this paper
• A Label-free Selected Reaction Monitoring Workflow Identifies a Subset of Pregnancy Specific Glycoproteins as Potential Predictive Markers of Early-onset Pre-eclampsia*

  2013cited by this paper
• Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma.

  2013cited by this paper
• Diversifying microRNA sequence and function

  2013cited by this paper
• Genetics of congenital heart disease: the glass half empty.

  2013cited by this paper
• Preliminary proteomic-based identification of a novel protein for Down's syndrome in maternal serum

  2012cited by this paper
• Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease.

  2012cited by this paper
• Genomic imprinting and its relevance to congenital disease, infertility, molar pregnancy and induced pluripotent stem cell

  2012cited by this paper
• Microdeletions and microduplications in patients with congenital heart disease and multiple congenital anomalies.

  2011cited by this paper
• Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.

  2011cited by this paper
• Advances in metabolite identification.

  2011cited by this paper
• The Contribution of Chromosomal Abnormalities to Congenital Heart Defects: A Population-Based Study

  2011cited by this paper
• Prenatal diagnosis of hypoplastic left heart syndrome in current era.

  2011cited by this paper
• Second trimester serum predictors of congenital heart defects in pregnancies without chromosomal or neural tube defects

  2011cited by this paper
• Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology.

  2010cited by this paper
• Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening

  2010cited by this paper
• Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery

  2010cited by this paper
• Identification of pregnancy-associated microRNAs in maternal plasma.

  2010cited by this paper
• Predictors of mortality in adult patients with congenital heart disease.

  2009cited by this paper
• Proteomic-Based Detection of a Protein Cluster Dysregulated during Cardiovascular Development Identifies Biomarkers of Congenital Heart Defects

  2009cited by this paper
• Proteomic technologies for prenatal diagnostics: advances and challenges ahead

  2009cited by this paper
• Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)

  2009cited by this paper
• Proteomics: Challenges, Techniques and Possibilities to Overcome Biological Sample Complexity

  2009cited by this paper
• A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

  2009cited by this paper
• Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma

  2008cited by this paper
• Noninvasive metabolomic profiling of embryo culture media using proton nuclear magnetic resonance correlates with reproductive potential of embryos in women undergoing in vitro fertilization.

  2008cited by this paper
• Maternal Global Methylation Status and Risk of Congenital Heart Diseases

  2008cited by this paper
• Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients.

  2007cited by this paper
• Congenital heart defects and maternal biomarkers of oxidative stress.

  2005cited by this paper
• Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism.

  2005cited by this paper
• Human genetics and disease: Human cytogenetics: 46 chromosomes, 46 years and counting

  2002cited by this paper
• Practical and theoretical implications of fetal-maternal lymphocyte transfer.

  1969cited by this paper

• Advancements in Pathogenic Genes and Biomarkers for Non-syndromic Cleft Lip With or Without Cleft Palate Via Multiomics

  2025cites this paper
• Isolation of donor gamma globulin obtained from multiparous women and its effects upon expression of HLA-G and HLA-DR molecules on lymphocytes from mothers of children with septal congenital heart defects

  2024cites this paper
• Biomarkers for congenital ventricular outflow tract malformations based on maternal serum lipid metabolomics analysis

  2024cites this paper
• Role of intergenic interactions between cytokine and Toll-like receptor genes in the etiology of congenital heart defects

  2023cites this paper
• CONTRIBUTION OF GENETIC PREDICTORS TO FORMATION OF HEALTH DEFICIENCY IN THE SEPARATE PERIOD AFTER CARDIAC SURGERY TREATMENT OF CONGENITAL HEART DEFECTS

  2023cites this paper
• The Lifelong Impact of Artificial Intelligence and Clinical Prediction Models on Patients With Tetralogy of Fallot

  2023cites this paper
• Expression pattern of HLA-G and HLA-DR molecules on lymphocytes of women and their children with septal congenital heart defects

  2023cites this paper
• Metabolomics: A New Tool in Our Understanding of Congenital Heart Disease

  2022cites this paper
• Maternal serum CFHR4 protein as a potential non-invasive marker of ventricular septal defects in offspring: evidence from a comparative proteomics study

  2022cites this paper
• Identifying biomarkers for prenatal diagnosis of neural tube defects based on “omics”

  2021cites this paper
• The trend in application of omics in type 2 diabetes researches; A bibliometric study.

  2021cites this paper
• Proteomics analysis of plasma protein changes in patent ductus arteriosus patients

  2020cites this paper